| Schedule of Disaggregation of Revenue |
Our product revenue, net breakdown is summarized below: | | | | | | | | | | | | | Three Months Ended March 31, | | (in thousands) | 2024 | | 2023 | | Product: | | | | RHA® Collection of dermal fillers | $ | 29,570 | | | $ | 30,280 | | DAXXIFY® | 22,149 | | | 15,378 | | Total product revenue, net | $ | 51,719 | | | $ | 45,658 | |
|
| Schedule of Contract with Customer, Contract Asset, Contract Liability, and Receivable |
Accounts receivable and contract liabilities from contracts with our product customers are as follows: | | | | | | | | | | | | | March 31, | | December 31, | | (in thousands) | 2024 | | 2023 | | Accounts receivable: | | | | Accounts receivable, gross | $ | 30,968 | | | $ | 27,975 | | Allowance for doubtful accounts | (1,081) | | | (950) | | | Total accounts receivable, net | $ | 29,887 | | | $ | 27,025 | | | | | | | Contract liabilities: | | | | | Deferred revenue, current | $ | 455 | | | $ | 884 | | | Total contract liabilities | $ | 455 | | | $ | 884 | |
Accounts receivable and contract liabilities from contracts with our collaboration customers are as follows: | | | | | | | | | | | | | March 31, | | December 31, | | (in thousands) | 2024 | | 2023 | Accounts receivable: | | | | Accounts receivable — Viatris | $ | — | | | $ | 631 | | Accounts receivable — Fosun | — | | | 4 | | Total accounts receivable | $ | — | | | $ | 635 | | | | | | | Contract liabilities: | | | | | Deferred revenue, current — Viatris | $ | 9,329 | | | $ | 9,853 | | | | | | | Total contract liabilities, current | $ | 9,329 | | | $ | 9,853 | | | | | | | Deferred revenue, non-current — Viatris | $ | 30,428 | | | $ | 29,444 | | | Deferred revenue, non-current — Fosun | 40,975 | | | 40,975 | | | Total contract liabilities, non-current | $ | 71,403 | | | $ | 70,419 | |
Changes in our contract liabilities from contracts with our collaboration revenue customers for the three months ended March 31, 2024 are as follows: | | | | | | | (in thousands) | | Balance on December 31, 2023 | $ | 80,272 | | | Revenue recognized | (217) | | | Billings and adjustments, net | 677 | | | Balance on March 31, 2024 | $ | 80,732 | |
|